Panzem® NCD

DRUG2 trials

Sponsors

CASI Pharmaceuticals, Inc.

Conditions

Metastatic Renal Cell CarcinomaProstate Cancer

Phase 2

Efficacy and Pharmacodynamic Study of Panzem® NCD in Patients With Hormone-Refractory Prostate Cancer

CompletedNCT00394810

CASI Pharmaceuticals, Inc.Prostate Cancer

Start: 2006-11-30End: 2008-11-30Updated: 2008-11-25

Phase 2 Study of Panzem® NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma

CompletedNCT00444314

CASI Pharmaceuticals, Inc.Metastatic Renal Cell Carcinoma

Start: 2007-02-28End: 2009-10-31Target: 82Updated: 2011-08-04